ClinicalTrials.gg
CompletedNCT05276570Updated Apr 9, 2026

Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

A Phase 1/2 interventional study of ARO-RAGE and Placebo in Asthma, sponsored by Arrowhead Pharmaceuticals. Completed at 8 sites in 5 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Arrowhead Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Apr 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Asthma with a site in New Zealand — 2 open to participants now, 4 under way, 3 of them phase 3. Asthma · New Zealand.

Enrollment
25th of 45
127 · median 138
Started
2022
with 2 others
Phase 1/2
4 of 45
1 open now
Registered
39th of 45
by date
Lead sponsor
3 of 45
Arrowhead Pharmaceuticals

Among the 45 studies in Asthma with a site in New Zealand, this one is the 25th largest by enrollment, is one of 3 that started in 2022, is one of 4 in phase 1/2, and was the 39th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 45 studies in Asthma with a site in New Zealand are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in New Zealand have not opened yet or have stopped. Only those recruiting at a site in New Zealand →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Asthma with a site in New Zealand, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ARO-RAGE in normal healthy volunteers (NHVs) and in participants with inflammatory lung disease (asthma). In Part 1 of the study, NHVs will receive a single dose of ARO-RAGE or placebo. In Part 2 of the study, adult participants with asthma will receive 2 doses of ARO-RAGE or placebo. Additional NHVs may be randomized to receive 1 or 2 doses of ARO-RAGE or placebo at Sponsor discretion. Dose levels in Part 2 will be determined based on cumulative safety and pharmacodynamic data from Part 1.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal pulmonary function tests at Screening (NHVs only)
  • Confirmed diagnosis of asthma based on source verifiable medical record (asthma patients only)
  • No abnormal finding of clinical relevance at Screening (other than asthma for asthma patients)
  • Stable dose of asthma controller medications prior to Screening (asthma patients only)
  • If on allergen-specific immunotherapy, participants must be on a stable maintenance dose
  • Non-smoking
  • Women of must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use . Males must not donate sperm during the study and for at least 12 weeks following the last dose of study drug
  • Willing to provide written and to comply with study requirements

Exclusion criteria

Exclusion Criteria:

  • Acute lower respiratory infection or asthma exacerbation within 30 days prior to first dose
  • Positive COVID-19 test during Screening window
  • Use of medication within 90 days prior to first dose
  • Receipt of any intranasal vaccine within 30 days prior to first dose
  • Use of systemic therapy within 90 days prior to first dose
  • health concerns (other than asthma in asthma patients)
  • (HIV) infection, seropositive for Virus (HBV), seropositive for Virus (HCV)
  • Uncontrolled hypertension
  • Unwilling to limit alcohol consumption to within moderate limits for the duration of the study
  • Use of illicit drugs
  • Use of an agent or device within 30 days prior to first dose

Note: additional inclusion/exclusion criteria may apply per protocol

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    ARO-RAGE

    ARO-RAGE Inhalation

    Drug: ARO-RAGE

  • Placebo comparator
    Placebo

    (0.9% NaCl)

    Drug: Placebo

Interventions

  • DrugARO-RAGE

    single or multiple doses of ARO-RAGE by inhalation of nebulized solution

  • DrugPlacebo

    calculated volume to match active treatment by inhalation of nebulized solution

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: From first dose of study drug through the end of study (EOS; up to 113 days)

Secondary outcomes

  1. Change from Baseline Over Time in Forced Expiratory Volume (FEV1)

    Time frame: Baseline through EOS (up to 113 days) or until serum soluble receptor for advance glycation end products (sRAGE) is ≥ 70% of baseline value

  2. Change from Baseline Over Time in Forced Vital Capacity (FVC)

    Time frame: Baseline through EOS (up to 113 days) or until serum sRAGE is ≥ 70% of baseline value

  3. Change from Baseline Over Time in Diffusing Capacity for Carbon Monoxide (DLCO)

    Time frame: Baseline through EOS (up to 113 days) or until serum sRAGE is ≥ 70% of baseline value

  4. PK of ARO-RAGE: Maximum Observed Plasma Concentration (Cmax)

    Time frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma

  5. PK of ARO-RAGE: Time to Maximum Observed Plasma Concentration (Tmax)

    Time frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma

  6. PK of ARO-RAGE: Area Under the Plasma Concentration versus Time Curve From Zero to 24 Hours (AUC0-24)

    Time frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma

  7. PK of ARO-RAGE: Area Under the Plasma Concentration versus Time Curve From Zero to the Last Quantifiable Plasma Concentration (AUClast)

    Time frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma

  8. PK of ARO-RAGE: Area Under the Plasma Concentration versus Time Curve From Zero to Infinity (AUCinf)

    Time frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma

  9. PK of ARO-RAGE: Terminal Elimination Half-Life (t1/2)

    Time frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma

  10. PK of ARO-RAGE: Apparent Systemic Clearance (CL/F)

    Time frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma

  11. PK of ARO-RAGE: Apparent Terminal-Phase Volume of Distribution (VZ/F)

    Time frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma

  12. PK of ARO-RAGE: Recovery of Unchanged Drug in Urine Over 0 to 24 Hours (Amount Excreted; Ae)

    Time frame: Through 24 hours post-dose

  13. PK of ARO-RAGE: Percentage of Administrated Drug Recovered in Urine Over 0 to 24 hours

    Time frame: Through 24 hours post-dose

  14. PK of ARO-RAGE: Renal Clearance (CLr)

    Time frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma

07

Study locations

8 sites
  • Research Site 1
    Nedlands, Washington 6009, Australia
  • Research Site 1
    Auckland, 1010, New Zealand
  • Research Site 2
    Auckland, 1051, New Zealand
  • Research Site 3
    Auckland, 622, New Zealand
  • Research Site 2
    Krakow, 31-455, Poland
  • Research Site 3
    Oświęcim, 32-600, Poland
  • Research Site 1
    Barcelona, 08017, Spain
  • Research Site 1
    Bangkok Noi, Bangkok 10700, Thailand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Apr 2025, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2022
First posted
Mar 11, 2022
StartActual
Jun 29, 2022
Primary completionActual
Apr 16, 2025
CompletionActual
Apr 16, 2025
Results delay requested
Apr 1, 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05276570
Responsible party
Sponsor
First posted
Mar 11, 2022
Start date
Jun 29, 2022
Primary completion
Apr 16, 2025
Completion
Apr 16, 2025
Last update
Apr 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion